Invitae Corporation
Index- P/E- EPS (ttm)-13.48 Insider Own1.40% Shs Outstand232.12M Perf Week5.34%
Market Cap630.88M Forward P/E- EPS next Y-1.64 Insider Trans-3.81% Shs Float228.85M Perf Month-2.47%
Income-3108.60M PEG- EPS next Q-0.58 Inst Own84.30% Short Float16.75% Perf Quarter-12.38%
Sales500.80M P/S1.26 EPS this Y59.80% Inst Trans6.47% Short Ratio2.06 Perf Half Y-66.46%
Book/sh1.66 P/B1.66 EPS next Y37.40% ROA-72.90% Target Price2.71 Perf Year-89.56%
Cash/sh3.18 P/C0.87 EPS next 5Y8.00% ROE-133.50% 52W Range1.83 - 29.15 Perf YTD-81.93%
Dividend- P/FCF- EPS past 5Y9.90% ROI-7.70% 52W High-90.53% Beta1.62
Dividend %- Quick Ratio6.10 Sales past 5Y79.00% Gross Margin21.90% 52W Low50.82% ATR0.34
Employees2300 Current Ratio6.40 Sales Q/Q17.50% Oper. Margin- RSI (14)47.49 Volatility10.02% 11.82%
OptionableYes Debt/Eq4.14 EPS Q/Q- Profit Margin- Rel Volume0.43 Prev Close2.86
ShortableYes LT Debt/Eq4.12 EarningsAug 09 AMC Payout- Avg Volume18.59M Price2.76
Recom3.30 SMA20-7.15% SMA50-12.01% SMA200-56.16% Volume8,014,762 Change-3.50%
Aug-25-22Initiated Credit Suisse Underperform $1
Aug-10-22Downgrade JP Morgan Neutral → Underweight
Jul-26-22Downgrade Cowen Outperform → Market Perform $8 → $2.50
Jul-21-22Downgrade Raymond James Outperform → Mkt Perform
Jul-20-22Downgrade Ladenburg Thalmann Buy → Neutral
Jul-19-22Downgrade The Benchmark Company Buy → Hold
Jul-19-22Downgrade SVB Leerink Outperform → Mkt Perform
Jun-03-22Initiated Piper Sandler Underweight $2.50
Aug-04-21Upgrade The Benchmark Company Hold → Buy $35
Jun-15-21Initiated Raymond James Outperform $37
Jun-03-21Initiated Goldman Neutral $33
May-25-21Initiated Wells Fargo Equal Weight $30
Apr-05-21Upgrade Oppenheimer Perform → Outperform $48
Feb-18-21Upgrade Ladenburg Thalmann Neutral → Buy $46.50 → $58
Feb-01-21Downgrade Oppenheimer Outperform → Perform
Oct-14-20Downgrade JP Morgan Overweight → Neutral
Sep-09-20Initiated Morgan Stanley Equal-Weight $38
Jul-01-20Downgrade The Benchmark Company Buy → Hold
Aug-07-19Reiterated The Benchmark Company Buy $26 → $28
Mar-04-19Initiated Chardan Capital Markets Buy $29
Oct-03-22 11:43AM
Sep-27-22 07:30AM
Sep-23-22 02:35PM
Sep-22-22 11:00AM
Sep-21-22 11:09AM
08:30AM Loading…
Sep-20-22 08:30AM
Sep-15-22 04:00PM
Sep-13-22 06:25PM
Sep-12-22 07:30AM
Sep-07-22 10:26AM
Sep-06-22 11:18AM
Sep-01-22 10:00AM
Aug-30-22 04:05PM
06:15AM Loading…
Aug-29-22 06:15AM
Aug-27-22 08:00AM
Aug-25-22 12:10PM
Aug-23-22 05:52AM
Aug-21-22 10:37AM
Aug-20-22 10:30AM
Aug-19-22 05:50PM
Aug-18-22 09:15AM
Aug-15-22 08:27AM
Aug-14-22 10:23AM
Aug-13-22 05:31AM
Aug-12-22 10:02PM
Aug-11-22 02:43PM
03:54PM Loading…
Aug-10-22 03:54PM
Aug-09-22 05:25PM
Aug-08-22 06:25PM
Aug-04-22 07:15PM
Aug-02-22 09:11AM
Jul-29-22 06:20PM
Jul-27-22 10:02AM
Jul-26-22 10:01AM
Jul-21-22 06:45PM
Jul-19-22 03:42PM
Jul-18-22 04:13PM
Jul-08-22 07:29AM
Jul-02-22 07:15AM
Jun-20-22 05:15AM
Jun-03-22 04:45PM
Jun-01-22 04:42PM
May-31-22 05:31AM
May-27-22 07:00AM
May-26-22 05:05PM
May-21-22 08:00AM
May-19-22 06:30AM
May-16-22 09:00AM
May-13-22 04:17PM
May-06-22 05:11AM
May-05-22 03:33PM
May-04-22 11:12AM
May-03-22 10:00PM
Apr-28-22 11:07AM
Apr-26-22 06:00PM
Apr-20-22 06:59AM
Apr-11-22 11:28AM
Apr-04-22 06:30AM
Mar-30-22 08:05AM
Mar-29-22 06:30AM
Mar-22-22 03:50PM
Mar-21-22 02:25PM
Mar-17-22 06:30AM
Mar-16-22 02:35PM
Mar-15-22 04:30PM
Mar-09-22 11:23AM
Feb-24-22 06:10PM
Feb-23-22 10:59AM
Feb-16-22 03:00AM
Feb-10-22 06:59AM
Feb-09-22 03:01PM
Feb-08-22 09:38AM
Feb-04-22 03:08PM
Feb-03-22 11:28PM
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WERNER ROBERT F.Chief Accounting OfficerAug 25Sale3.451,3504,658251,307Aug 29 04:20 PM
Brida ThomasSee remarksAug 16Sale4.557,04832,071386,267Aug 18 04:24 PM
Nussbaum Robert LChief Medical OfficerAug 16Sale4.557,04832,071396,532Aug 18 04:22 PM
WERNER ROBERT F.Chief Accounting OfficerAug 16Sale4.553,25214,798198,657Aug 18 04:21 PM
George Sean EDirectorAug 16Sale4.5522,085100,493788,656Aug 18 04:21 PM
WERNER ROBERT F.Chief Accounting OfficerMay 19Sale3.402,7469,336201,909May 19 07:06 PM
WERNER ROBERT F.Chief Accounting OfficerMay 17Sale3.817,35628,027204,655May 19 07:06 PM
Knight Kenneth D.Chief Operating OfficerMay 17Sale3.8128,295107,807518,895May 19 05:45 PM
Brida ThomasSee RemarksMay 17Sale3.816,09823,234393,315May 19 05:30 PM
George Sean EPresident & CEOMay 17Sale3.8118,29669,710794,691May 19 05:28 PM
Wen YafeiChief Financial OfficerMay 17Sale3.8117,04264,932344,374May 19 05:27 PM
Nussbaum Robert LChief Medical OfficerMay 17Sale3.816,09823,234403,580May 19 05:26 PM
George Sean EPresident & CEOMar 14Sale6.6931,389209,886812,987Mar 16 08:56 PM
Wen YafeiChief Financial OfficerMar 14Sale6.693,28921,992136,416Mar 16 08:54 PM
Brida ThomasGeneral CounselMar 14Sale6.6917,987120,286229,739Mar 16 08:55 PM
Nussbaum Robert LChief Medical OfficerMar 14Sale6.6919,588130,993241,167Mar 16 08:52 PM
Knight Kenneth D.Chief Operating OfficerMar 14Sale6.692,35815,767322,190Mar 21 04:31 PM
Nussbaum Robert LChief Medical OfficerNov 11Option Exercise10.0829,675299,196275,725Nov 15 05:07 PM
Nussbaum Robert LChief Medical OfficerNov 11Sale21.8929,675649,568246,050Nov 15 05:07 PM
George Sean EPresident & CEOOct 22Sale28.063,675103,120800,259Oct 26 05:49 PM